Impact of neuroprotective therapy on cognition and oxidative stress in the early stages of Parkinson’s disease

A. V.  Demchenko; V. V. Biriuk

doi:10.14739/2310-1237.2021.3.247142

Authors

A. V. Demchenko Zaporizhzhia State Medical University, Ukraine, Ukraine https://orcid.org/0000-0002-4296-0902
V. V. Biriuk Zaporizhzhia State Medical University, Ukraine, Ukraine https://orcid.org/0000-0001-8826-1536

DOI:

https://doi.org/10.14739/2310-1237.2021.3.247142

Keywords:

Parkinson’s disease, early stages, neuroprotector, cognitive impairment, glutathione peroxidase

Abstract

The aim of this study was to investigate the clinical and biochemical efficiency of citicoline in cognitive improvement and changes of glutathione peroxidase (GPx) blood plasma levels in patients at early stages of Parkinson’s disease (PD).

Materials and methods. We recruited 42 patients at I–II Hoehn and Yahr PD stages and 20 controls. The Montreal Cognitive Assessment test (MoCA) was used to assess several cognitive domains in PD patients (before citicoline treatment, after intravenous therapy and after pills therapy) and controls (once). Plasma was collected once in controls and twice in PD patients (on the first and the last days of observation). Citicoline was administrated to 23 of 42 PD patients in addition to basic antiparkinsonian therapy intravenously during 10 days and with pills during next 30 days. The rest 19 of 42 PD patients had been taking basic antiparkinsonian treatment only (comparison group).

Results. We observed significant improvement of MoCA scores in PD patients with citicoline course (PD-Cs) in each check day. But in spite of such an improvement in PD patients, who were left on the basic antiparkinsonian treatment (PD-Bs), on the 10^th day of observation, patients of this group did not keep it to the last day of the research (P < 0.001). After the treatment the GPx level in plasma of PD-Cs was significantly higher than in PD-Bs (P < 0.001). Furthermore, the activity of GPx plasma level after citicoline course was significantly higher than before additional neuroprotective therapy, which wasn’t observed in PD patients on basic treatment only.

Conclusion. The cognition of PD patients (according to MoCA scores) at the early stages of the disease was significantly improved after citicoline treatment. Citicoline treatment had significant positive influence on the increasing antioxidant GPx plasma activity in PD patients at the early stages of the disease.

Author Biographies

A. V. Demchenko, Zaporizhzhia State Medical University, Ukraine

MD, PhD, DSc, Associate Professor of the Department of Family Medicine, Therapy, Cardiology and Neurology of FPE

V. V. Biriuk, Zaporizhzhia State Medical University, Ukraine

MD, PhD-student of the Department of Family Medicine, Therapy, Cardiology and Neurology of FPE

References

Jagmag, S. A., Tripathi, N., Shukla, S. D., Maiti, S., & Khurana, S. (2016). Evaluation of Models of Parkinson's Disease. Frontiers in neuroscience, 9, 503. https://doi.org/10.3389/fnins.2015.00503

Kouli, A., Torsney, K. M., & Kuan, W. L. (2018). Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. In T. B. Stoker, J. C. Greenland (Eds.), Parkinson’s Disease: Pathogenesis and Clinical Aspects. Codon Publications. https://exonpublications.com/index.php/exon/article/view/186

Xu, L., & Pu, J. (2016). Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application. Parkinson's disease, 2016, 1720621. https://doi.org/10.1155/2016/1720621

Musgrove, R. E., Helwig, M., Bae, E. J., Aboutalebi, H., Lee, S. J., Ulusoy, A., & Di Monte, D. A. (2019). Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular α-synuclein transfer. The Journal of clinical investigation, 129(9), 3738-3753. https://doi.org/10.1172/JCI127330

Que, D. S., & Jamora, R. (2021). Citicoline as Adjuvant Therapy in Parkinson's Disease: A Systematic Review. Clinical therapeutics, 43(1), e19-e31. https://doi.org/10.1016/j.clinthera.2020.11.009

Iulia, C., Ruxandra, T., Costin, L. B., & Liliana-Mary, V. (2017). Citicoline - a neuroprotector with proven effects on glaucomatous disease. Romanian journal of ophthalmology, 61(3), 152-158. https://doi.org/10.22336/rjo.2017.29

Sarıkaya, E., Doğan S. (2020). Glutathione Peroxidase in Health and Diseases. In M. D. Bagatini (Ed.), Glutathione System and Oxidative Stress in Health and Disease, IntechOpen, https://doi.org/10.5772/intechopen.91009

Li, Z., Wang, P., Yu, Z., Sun, H., Zhang, J., Zhang, J., Cong, Y., Sun, C., Zhang, Y. G., & Ju, X. (2016). Effect of citicoline adjuvant therapy on mild cognitive impairment in Parkinson’s disease. International Journal of Clinical and Experimental Medicine, 9(2), 4593-4598.

Ahmed, M., Herrmann, N., Chen, J. J., Saleem, M., Oh, P. I., Andreazza, A. C., Kiss, A., & Lanctôt, K. L. (2021). Glutathione Peroxidase Activity Is Altered in Vascular Cognitive Impairment-No Dementia and Is a Potential Marker for Verbal Memory Performance. Journal of Alzheimer's disease : JAD, 79(3), 1285-1296. https://doi.org/10.3233/JAD-200754

Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., Halliday, G., Goetz, C. G., Gasser, T., Dubois, B., Chan, P., Bloem, B. R., Adler, C. H., & Deuschl, G. (2015). MDS clinical diagnostic criteria for Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 30(12), 1591-1601. https://doi.org/10.1002/mds.26424

Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53(4), 695-699. https://doi.org/10.1111/j.1532-5415.2005.53221.x

Salamon, A., Zádori, D., Szpisjak, L., Klivényi, P., & Vécsei, L. (2020). Neuroprotection in Parkinson's disease: facts and hopes. Journal of neural transmission, 127(5), 821-829. https://doi.org/10.1007/s00702-019-02115-8

Sarkar, S., Raymick, J., & Imam, S. (2016). Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. International journal of molecular sciences, 17(6), 904. https://doi.org/10.3390/ijms17060904

Vida, C., Kobayashi, H., Garrido, A., Martínez de Toda, I., Carro, E., Molina, J. A., & De la Fuente, M. (2019). Lymphoproliferation Impairment and Oxidative Stress in Blood Cells from Early Parkinson's Disease Patients. International journal of molecular sciences, 20(3), 771. https://doi.org/10.3390/ijms20030771

Wei, Z., Li, X., Li, X., Liu, Q., & Cheng, Y. (2018). Oxidative Stress in Parkinson's Disease: A Systematic Review and Meta-Analysis. Frontiers in molecular neuroscience, 11, 236. https://doi.org/10.3389/fnmol.2018.00236

Jasielski, P., Piędel, F., Piwek, M., Rocka, A., Petit, V., & Rejdak, K. (2020). Application of Citicoline in Neurological Disorders: A Systematic Review. Nutrients, 12(10), 3113. https://doi.org/10.3390/nu12103113

Gareri, P., Cotroneo, A. M., Orsitto, G., & Putignano, S. (2020). The CITIMEM study: A pilot study. Optimizing pharmacological treatment in dementia. Archives of gerontology and geriatrics, 89, 104073. https://doi.org/10.1016/j.archger.2020.104073

Demchenko, A. V., Belenichev, I. F., & Bobrova, V. I. (2016). Farmakolohichna korektsiia stanu systemy hlutationu krovi khvorykh na khronichnu ishemiiu mozku Pharmacological correction of glutathione system state in the patients with chronic cerebral ischemia. Farmakolohiia ta likarska toksykolohiia, (6), 89-96. [in Ukrainian].